Gene expression profiling concerning mineralization in human dental pulp cells treated with mineral trioxide aggregate.
BACKGROUND
This study investigated changes in gene expressions related to mineralization when mineral trioxide aggregate (MTA) is applied in vitro to human dental pulp cells (HDPCs).


METHODS
MTA in a Teflon tube (diameter 10 mm, height 2 mm) was applied to HDPCs. Empty tube-applied HDPCs were used as negative control. Total RNA was extracted at 6, 24, and 72 hours after MTA application for microarray analysis. The results were confirmed selectively by performing reverse transcriptase-polymerase chain reaction for genes that showed changes of more than 2-fold or less than half.


RESULTS
Of the 24,546 genes, 109 genes were up-regulated more than 2-fold (eg, THBS1, VCAN, BHLHB2, FN1, COL10A1, TUFT1, and HMOX1), and 69 genes were down-regulated below 50% (eg, DCN, SOCS2, and IL8).


CONCLUSIONS
These results suggest that rather than being a bio-inert material, MTA affects pulp cells in various ways. MTA appears to affect mineralization and induces slight inflammation and protective role against slight inflammation.
Department of Conservative Dentistry, School of Dentistry & Dental Research Institute, Seoul National University, Seoul, Korea.
Yong-Beom
YB
Kim
Won-Jun
WJ
Shon
Woocheol
W
Lee
Kee-Yeon
KY
Kum
Seung-Ho
SH
Baek
Kwang-Shik
KS
Bae
D017607:Aluminum Compounds / Q000494:pharmacology*; D051792:Basic Helix-Loop-Helix Proteins / Q000187:drug effects; D001672:Biocompatible Materials / Q000494:pharmacology; D002113:Calcification, Physiologic / Q000235:genetics*; D017610:Calcium Compounds / Q000494:pharmacology*; D024121:Collagen Type X / Q000187:drug effects; D058575:Decorin / Q000187:drug effects; D003746:Dental Enamel Proteins / Q000187:drug effects; D003782:Dental Pulp / Q000166:cytology / Q000187:drug effects*; D004338:Drug Combinations; D005353:Fibronectins / Q000187:drug effects; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D051547:Heme Oxygenase-1 / Q000187:drug effects; D018398:Homeodomain Proteins / Q000187:drug effects; D006801:Humans; D016209:Interleukin-8 / Q000187:drug effects; D046228:Microarray Analysis; D010087:Oxides / Q000494:pharmacology*; D012313:RNA / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012387:Root Canal Filling Materials / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D017640:Silicates / Q000494:pharmacology*; D050826:Suppressor of Cytokine Signaling Proteins / Q000187:drug effects; D019700:Thrombospondin 1 / Q000187:drug effects; D013997:Time Factors; D053675:Versicans / Q000187:drug effects
D017607:Aluminum Compounds; D051792:Basic Helix-Loop-Helix Proteins; D001672:Biocompatible Materials; D017610:Calcium Compounds; D024121:Collagen Type X; D058575:Decorin; D003746:Dental Enamel Proteins; D004338:Drug Combinations; D005353:Fibronectins; D051547:Heme Oxygenase-1; D018398:Homeodomain Proteins; D016209:Interleukin-8; D010087:Oxides; D012313:RNA; D012387:Root Canal Filling Materials; D017640:Silicates; D050826:Suppressor of Cytokine Signaling Proteins; D019700:Thrombospondin 1; D053675:Versicans; C107989:BHLHE40 protein, human; C546878:DCN protein, human; C106643:SOCS2 protein, human; C508322:VCAN protein, human; C086631:mineral trioxide aggregate; C038456:tuftelin; C496541:HMOX1 protein, human